Primary hyperoxaluria type II and organ transplantation

Fang Yiling; Miao Yun

doi:10.3969/j.issn.1674-7445.2023145

Volume 14 Issue 6

Nov. 2023

Turn off MathJax

Article Contents

Article Navigation > ORGAN TRANSPLANTATION > 2023 > 14(6): 804-809

Fang Yiling, Miao Yun. Primary hyperoxaluria type II and organ transplantation[J]. ORGAN TRANSPLANTATION, 2023, 14(6): 804-809. doi: 10.3969/j.issn.1674-7445.2023145

Citation:

Fang Yiling, Miao Yun. Primary hyperoxaluria type II and organ transplantation[J]. ORGAN TRANSPLANTATION, 2023, 14(6): 804-809. doi: 10.3969/j.issn.1674-7445.2023145

Citation:

Fang Yiling, Miao Yun. Primary hyperoxaluria type II and organ transplantation[J]. ORGAN TRANSPLANTATION, 2023, 14(6): 804-809. doi: 10.3969/j.issn.1674-7445.2023145

PDF( 673 KB)

Primary hyperoxaluria type II and organ transplantation

doi: 10.3969/j.issn.1674-7445.2023145

Fang Yiling,
Miao Yun^,

Department of Organ Transplantation, Nanfang Hospital of Southern Medical University, Guangzhou 510515, China

More Information

Corresponding author: Miao Yun, Email: miaoyunecho@126.com
Received Date: 2023-07-23
Accepted Date: 2023-09-19

Available Online: 2023-10-11

Publish Date: 2023-11-09

Abstract

Abstract

Primary hyperoxaluria type Ⅱ (PH2) is an inherited disorder of the glyoxylate metabolism caused by the gene mutation of glyoxylate reductase/hydroxypyruvate reductase (GRHPR). PH2 is characterized by recurrent nephrolithiasis and nephrocalcinosis, which may even progress into end-stage renal disease. Currently, organ transplantation is the only treatment option for PH2, which mainly includes two strategies: kidney transplantation and combined liver and kidney transplantation. Kidney transplantation yields a high risk of recurrence of oxalate nephropathy, which may cause early graft dysfunction. Combined liver and kidney transplantation could mitigate the deficiency of oxalate metabolism, whereas it yields a high risk of graft complications. PH2 is an extremely rare disorder. No consensus has been reached on the indications, surgical selection and perioperative management of organ transplantation for PH2 patients. In this article, the pathogenesis, diagnosis, monitoring and organ transplantation experience of PH2 were reviewed, aiming to divert clinicians' attention to PH2 and provide reference for determining diagnosis and treatment regimens, especially transplantation strategy for PH2 patients.
- Primary hyperoxaluria type Ⅱ,
- Kidney stone,
- End-stage renal disease (ESRD),
- Kidney transplantation,
- Combined liver and kidney transplantation,
- Calcium oxalate stone

FullText(HTML)

References(38)

References

[1]	王心悦, 詹浩苏, 孙丽莹. 中国大陆原发性高草酸尿症1型临床特点及诊治情况总结[J]. 器官移植, 2022, 13(2): 232-239. DOI: 10.3969/j.issn.1674-7445.2022.02.012. WANG XY, ZHAN HS, SUN LY. Summary of clinical characteristics, diagnosis and treatment of primary hyperoxaluria type 1 in mainland China[J]. Organ Transplant, 2022, 13(2): 232-239. DOI: 10.3969/j.issn.1674-7445.2022.02.012.
[2]	SINGH P, VIEHMAN JK, MEHTA RA, et al. Clinical characterization of primary hyperoxaluria type 3 in comparison with types 1 and 2[J]. Nephrol Dial Transplant, 2022, 37(5): 869-875. DOI: 10.1093/ndt/gfab027.
[3]	SHEE K, STOLLER ML. Perspectives in primary hyperoxaluria - historical, current and future clinical interventions[J]. Nat Rev Urol, 2022, 19(3): 137-146. DOI: 10.1038/s41585-021-00543-4.
[4]	MANDRILE G, PELLE A, SCIANNAMEO V, et al. Primary hyperoxaluria in Italy: the past 30 years and the near future of a (not so) rare disease[J]. J Nephrol, 2022, 35(3): 841-850. DOI: 10.1007/s40620-022-01258-4.
[5]	SIKORA P, ZANIEW M, GRENDA R, et al. Still diagnosed too late and under-recognized? the first comprehensive report on primary hyperoxaluria in Poland[J]. Pol Arch Intern Med, 2020, 130(12): 1053-1063. DOI: 10.20452/pamw.15698.
[6]	CRIVELLI JJ, MITCHELL T, KNIGHT J, et al. Contribution of dietary oxalate and oxalate precursors to urinary oxalate excretion[J]. Nutrients, 2020, 13(1): 62. DOI: 10.3390/nu13010062.
[7]	CAPOLONGO G, FERRARO PM, UNWIN R. Inflammation and kidney stones: cause and effect?[J]. Curr Opin Urol, 2023, 33(2): 129-135. DOI: 10.1097/MOU.0000000000001066.
[8]	DEMOULIN N, AYDIN S, GILLION V, et al. Pathophysiology and management of hyperoxaluria and oxalate nephropathy: a review[J]. Am J Kidney Dis, 2022, 79(5): 717-727. DOI: 10.1053/j.ajkd.2021.07.018.
[9]	PIJNENBURG L, CAILLARD S, BOIVIN G, et al. Type 1 primary hyperoxaluria: a case report and focus on bone impairment of systemic oxalosis[J]. Morphologie, 2018, 102(336): 48-53. DOI: 10.1016/j.morpho.2017.09.004.
[10]	BIRTEL J, DIEDEREN RM, HERRMANN P, et al. The retinal phenotype in primary hyperoxaluria type 2 and 3[J]. Pediatr Nephrol, 2023, 38(5): 1485-1490. DOI: 10.1007/s00467-022-05765-1.
[11]	LEE DH, KASPROWICZ T, MORALES A, et al. A case of infiltrative cardiomyopathy secondary to primary hyperoxaluria type 2 - utilization of multimodality imaging[J]. Cureus, 2021, 13(9): e17914. DOI: 10.7759/cureus.17914.
[12]	DEVRESSE A, COCHAT P, GODEFROID N, et al. Transplantation for primary hyperoxaluria type 1: designing new strategies in the era of promising therapeutic perspectives[J]. Kidney Int Rep, 2020, 5(12): 2136-2145. DOI: 10.1016/j.ekir.2020.09.022.
[13]	COCHAT P, RUMSBY G. Primary hyperoxaluria[J]. N Engl J Med, 2013, 369(7): 649-658. DOI: 10.1056/NEJMra1301564.
[14]	GARRELFS SF, RUMSBY G, PETERS-SENGERS H, et al. Patients with primary hyperoxaluria type 2 have significant morbidity and require careful follow-up[J]. Kidney Int, 2019, 96(6): 1389-1399. DOI: 10.1016/j.kint.2019.08.018.
[15]	HOSAAGRAHARA RAMAKRISHNA S, HASSAN A, KASALA MB, et al. Pediatric combined living donor liver and kidney transplantation for primary hyperoxaluria type 2[J]. Am J Transplant, 2023, 23(10): 1622-1625. DOI: 10.1016/j.ajt.2023.05.006.
[16]	MANDRILE G, BECK B, ACQUAVIVA C, et al. Genetic assessment in primary hyperoxaluria: why it matters[J]. Pediatr Nephrol, 2023, 38(3): 625-634. DOI: 10.1007/s00467-022-05613-2.
[17]	詹睿超, 葛玉成, 张道新, 等. 原发性高草酸尿症基因型与表型的研究进展[J]. 国际外科学杂志, 2021, 48(3): 203-207. DOI: 10.3760/cma.j.cn115396-20200319-00072. ZHAN RC, GE YC, ZHANG DX, et al. Research progress on genotype and phenotype of primary hyperoxaluria[J]. Int J Surg, 2021, 48(3): 203-207. DOI: 10.3760/cma.j.cn115396-20200319-00072.
[18]	GROOTHOFF JW, METRY E, DEESKER L, et al. Clinical practice recommendations for primary hyperoxaluria: an expert consensus statement from ERKNet and OxalEurope[J]. Nat Rev Nephrol, 2023, 19(3): 194-211. DOI: 10.1038/s41581-022-00661-1.
[19]	ZHAO F, BERGSTRALH EJ, MEHTA RA, et al. Predictors of incident ESRD among patients with primary hyperoxaluria presenting prior to kidney failure[J]. Clin J Am Soc Nephrol, 2016, 11(1): 119-126. DOI: 10.2215/CJN.02810315.
[20]	INJEYAN M, BIDAULT V, BACCHETTA J, et al. Hydration and nephrolithiasis in pediatric populations: specificities and current recommendations[J]. Nutrients, 2023, 15(3): 728. DOI: 10.3390/nu15030728.
[21]	冯潇雨, 程娜, 张荣军, 等. 儿童原发性高草酸尿症1型1例并文献复习[J]. 中国临床研究, 2021, 34(9): 1245-1249. DOI: 10.13429/j.cnki.cjcr.2021.09.021. FENG XY, CHENG N, ZHANG RJ, et al. A case of primary hyperoxaluria type 1 in children and literature review[J]. Chin J Clin Res, 2021, 34(9): 1245-1249. DOI: 10.13429/j.cnki.cjcr.2021.09.021.
[22]	BHASIN B, ÜREKLI HM, ATTA MG. Primary and secondary hyperoxaluria: understanding the enigma[J]. World J Nephrol, 2015, 4(2): 235-244. DOI: 10.5527/wjn.v4.i2.235.
[23]	BOSE KS, SARMA RH. Delineation of the intimate details of the backbone conformation of pyridine nucleotide coenzymes in aqueous solution[J]. Biochem Biophys Res Commun, 1975, 66(4): 1173-1179. DOI: 10.1016/0006-291x(75)90482-9.
[24]	MASSY ZA, DRUEKE TB. Running interference: lumasiran and other RNA interference therapeutics for kidney diseases[J]. Kidney Int, 2022, 101(2): 208-211. DOI: 10.1016/j.kint.2021.05.027.
[25]	METRY EL, VAN DIJK LMM, PETERS-SENGERS H, et al. Transplantation outcomes in patients with primary hyperoxaluria: a systematic review[J]. Pediatr Nephrol, 2021, 36(8): 2217-2226. DOI: 10.1007/s00467-021-05043-6.
[26]	CORNELL LD, AMER H, VIEHMAN JK, et al. Posttransplant recurrence of calcium oxalate crystals in patients with primary hyperoxaluria: incidence, risk factors, and effect on renal allograft function[J]. Am J Transplant, 2022, 22(1): 85-95. DOI: 10.1111/ajt.16732.
[27]	GUPTA A, SOMERS MJG, BAUM MA. Treatment of primary hyperoxaluria type 1[J]. Clin Kidney J, 2022, 15(Suppl 1): i9-i13. DOI: 10.1093/ckj/sfab232.
[28]	LAM CW, YUEN YP, LAI CK, et al. Novel mutation in the GRHPR gene in a Chinese patient with primary hyperoxaluria type 2 requiring renal transplantation from a living related donor[J]. Am J Kidney Dis, 2001, 38(6): 1307-1310. DOI: 10.1053/ajkd.2001.29229.
[29]	NADERI G, LATIF A, TABASSOMI F, et al. Failure of isolated kidney transplantation in a pediatric patient with primary hyperoxaluria type 2[J]. Pediatr Transplant, 2014, 18(3): E69-E73. DOI: 10.1111/petr.12240.
[30]	LIU S, GAO B, WANG G, et al. Recurrent primary hyperoxaluria type 2 leads to early post-transplant renal function loss: a case report[J]. Exp Ther Med, 2018, 15(4): 3169-3172. DOI: 10.3892/etm.2018.5841.
[31]	DHONDUP T, LORENZ EC, MILLINER DS, et al. Combined liver-kidney transplantation for primary hyperoxaluria type 2: a case report[J]. Am J Transplant, 2018, 18(1): 253-257. DOI: 10.1111/ajt.14418.
[32]	DEL BELLO A, COINTAULT O, DELAS A, et al. Recurrence of oxalate nephropathy after isolated kidney transplantation for primary hyperoxaluria type 2[J]. Am J Transplant, 2018, 18(2): 525-526. DOI: 10.1111/ajt.14550.
[33]	DEL BELLO A, COINTAULT O, DELAS A, et al. Primary hyperoxaluria type 2 successfully treated with combined liver-kidney transplantation after failure of isolated kidney transplantation[J]. Am J Transplant, 2020, 20(6): 1752-1753. DOI: 10.1111/ajt.15829.
[34]	JIA Z, ZHONG Q, LIN T, et al. Subsequent liver transplantation did not reverse recurrence of oxalate nephropathy after isolated kidney transplantation for primary type 2 hyperoxaluria[J]. Asian J Surg, 2022, 45(1): 483-485. DOI: 10.1016/j.asjsur.2021.08.066.
[35]	GENENA KM, SAS DJ, MILLINER DS, et al. Successful treatment of primary hyperoxaluria type 2 with a combined liver and kidney transplant[J]. Kidney Int Rep, 2023, 8(7): 1469-1472. DOI: 10.1016/j.ekir.2023.03.013.
[36]	YAU AA, HINDI J, URIBARRI J. Recurrent nephrolithiasis causing kidney failure[J]. Am J Kidney Dis, 2021, 77(4): A18-A21. DOI: 10.1053/j.ajkd.2020.04.020.
[37]	MONICO CG, MILLINER DS. Combined liver-kidney and kidney-alone transplantation in primary hyperoxaluria[J]. Liver Transpl, 2001, 7(11): 954-963. DOI: 10.1053/jlts.2001.28741.
[38]	SHASHA-LAVSKY H, AVNI A, PAZ Z, et al. Long-term outcomes after pre-emptive liver transplantation in primary hyperoxaluria type 1[J]. Pediatr Nephrol, 2023, 38(6): 1811-1820. DOI: 10.1007/s00467-022-05803-y.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(1) / Tables(1)

Get Citation

PDF

XML

Article Metrics

Article views (338) PDF downloads(37)

Primary hyperoxaluria type II and organ transplantation

doi: 10.3969/j.issn.1674-7445.2023145

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Primary hyperoxaluria type II and organ transplantation

doi: 10.3969/j.issn.1674-7445.2023145

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Export File

Citation

Format

Content